Lion TCR attracts $20 mln Series A
Singapore-based Lion TCR, a developer of engineered T-cell immunotherapy against viral-related cancer and chronic hepatitis B, has secured $20 million in Series A funding. The investors in this round included Yashang Capital and Westlake Ventures Capital.
29 May 2018•1 min read
